CRM1 inhibition induces tumor cell cytotoxicity and impairs osteoclastogenesis in multiple myeloma: Molecular mechanisms and therapeutic implications

Leukemia

Volumn 28, Issue 1, 2014, Pages 155-165

  Tai, Y T ^a   Landesman, Y ^b   Acharya, C ^a   Calle, Y ^c   Zhong, M Y ^a   Cea, M ^a   Tannenbaum, D ^a   Cagnetta, A ^a   Reagan, M ^a   Munshi, A A ^a   Senapedis, W ^b   Saint Martin, J R ^b   Kashyap, T ^b   Shacham, S ^b   Kauffman, M ^b   Gu, Y ^d   Wu, L ^d   Ghobrial, I ^a   Zhan, F ^e   Kung, A L ^e   Schey, S A ^f   Richardson, P ^a   Munshi, N C ^a   Anderson, K C ^a   more..

^a DANA FARBER CANCER INSTITUTE   (United States)

^b Karyopharm Therapeutics   (United States)

^c KING'S COLLEGE LONDON   (United Kingdom)

^d UNIVERSITY OF FLORIDA   (United States)

^e UNIVERSITY OF IOWA   (United States)

^f HARVARD MEDICAL SCHOOL   (United States)

Author keywords

multiple myeloma (MM); nuclear export protein; nuclear factor kB (NF kB) activation; osteoclasts (OC); selective inhibitors of nuclear export (SINEs) against CRM1 XPO1; tumor suppressors

Indexed keywords

BORTEZOMIB; CASPASE 3; CASPASE 7; CASPASE 9; EXPORTIN 1; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; KPT 185; KPT 251; KPT 276; KPT 330; MYC PROTEIN; OSTEOCLAST DIFFERENTIATION FACTOR; PROTEIN INHIBITOR; PROTEIN MCL 1; PROTEIN P53; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; BONE DENSITY; BONE LESION; BONE MARROW CELL; BONE MARROW STROMA CELL; CANCER INHIBITION; CANCER RESISTANCE; CANCER SURVIVAL; CELL CYCLE ARREST; CELL SURVIVAL; CELL VIABILITY; COCULTURE; CONTROLLED STUDY; DOWN REGULATION; DRUG CYTOTOXICITY; DRUG MECHANISM; EVENT FREE SURVIVAL; GENE EXPRESSION; GENE SILENCING; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; IMMUNOBLOTTING; MOUSE; MULTIPLE MYELOMA; NONHUMAN; OSTEOCLAST; OSTEOCLASTOGENESIS; OSTEOLYSIS; OVERALL SURVIVAL; PATHOPHYSIOLOGY; PLASMA CELL LEUKEMIA; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; TUMOR CELL; TUMOR VOLUME;

HUMANS; KARYOPHERINS; MULTIPLE MYELOMA; OSTEOCLASTS; RECEPTORS, CYTOPLASMIC AND NUCLEAR;

EID: 84891847971     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2013.115     Document Type: Article

References (46)

1. Xu D, Grishin NV, Chook YM. NESdb: a database of NES-containing CRM1 cargos. Mol Biol Cell 2012; 23: 3673-3676.
2. Kanai M, Hanashiro K, Kim SH, Hanai S, Boulares AH, Miwa M et al. Inhibition of Crm1-p53 interaction and nuclear export of p53 by poly(ADP-ribosyl)ation. Nat Cell Biol 2007; 9: 1175-1183. (Pubitemid 47500494)
3. Shao C, Lu C, Chen L, Koty PP, Cobos E, Gao W. p53-Dependent anticancer effects of leptomycin B on lung adenocarcinoma. Cancer Chemother Pharmacol 2011; 67: 1369-1380.
4. Turner JG, Dawson J, Sullivan DM. Nuclear export of proteins and drug resistance in cancer. Biochem Pharmacol 2012; 83: 1021-1032.
5. Vogt PK, Jiang H, Aoki M. Triple layer control: phosphorylation, acetylation and ubiquitination of FOXO proteins. Cell Cycle 2005; 4: 908-913. (Pubitemid 41359756)
6. Senapedis WT, Kennedy CJ, Boyle PM, Silver PA. Whole genome siRNA cell-based screen links mitochondria to Akt signaling network through uncoupling of electron transport chain. Mol Biol Cell 2011; 22: 1791-1805.
7. Huang TT, Kudo N, Yoshida M, Miyamoto S. A nuclear export signal in the N-terminal regulatory domain of IkappaBalpha controls cytoplasmic localization of inactive NF-kappaB/IkappaBalpha complexes. Proc Natl Acad Sci USA 2000; 97: 1014-1019. (Pubitemid 30080804)
8. Brodie KM, Henderson BR. Characterization of BRCA1 protein targeting, dynamics, and function at the centrosome: a role for the nuclear export signal, CRM1, and Aurora A kinase. J Biol Chem 2012; 287: 7701-7716.
9. Yao Y, Dong Y, Lin F, Zhao H, Shen Z, Chen P et al. The expression of CRM1 is associated with prognosis in human osteosarcoma. Oncol Rep 2009; 21: 229-235.
10. Huang WY, Yue L, Qiu WS, Wang LW, Zhou XH, Sun YJ. Prognostic value of CRM1 in pancreas cancer. Clin Invest Med 2009; 32: E315.
11. Noske A, Weichert W, Niesporek S, Roske A, Buckendahl AC, Koch I et al. Expression of the nuclear export protein chromosomal region maintenance/exportin 1/Xpo1 is a prognostic factor in human ovarian cancer. Cancer 2008; 112: 1733-1743. (Pubitemid 351536833)
12. van der Watt PJ, Maske CP, Hendricks DT, Parker MI, Denny L, Govender D et al. The Karyopherin proteins, Crm1 and Karyopherin beta1, are overexpressed in cervical cancer and are critical for cancer cell survival and proliferation. Int J Cancer 2009; 124: 1829-1840.
13. Puente XS, Pinyol M, Quesada V, Conde L, Ordonez GR, Villamor N et al. Whole-genome sequencing identifies recurrent mutations in chronic lymphocytic leukaemia. Nature 2011; 475: 101-105.
14. Balatti V, Bottoni A, Palamarchuk A, Alder H, Rassenti LZ, Kipps TJ et al. NOTCH1 mutations in CLL associated with trisomy 12. Blood 2012; 119: 329-331.
15. Turner JG, Engel R, Derderian JA, Jove R, Sullivan DM. Human topoisomerase IIalpha nuclear export is mediated by two CRM-1-dependent nuclear export signals. J Cell Sci 2004; 117: 3061-3071. (Pubitemid 39117680)
16. Turner JG, Sullivan DM. CRM1-mediated nuclear export of proteins and drug resistance in cancer. Curr Med Chem 2008; 15: 2648-2655.
17. Turner JG, Marchion DC, Dawson JL, Emmons MF, Hazlehurst LA, Washausen P et al. Human multiplemyeloma cells are sensitized to topoisomerase II inhibitors by CRM1 inhibition. Cancer Res 2009; 69: 6899-6905.
18. Newlands ES, Rustin GJ, Brampton MH. Phase I trial of elactocin. Br J Cancer 1996; 74: 648-649. (Pubitemid 26279064)
19. Sakakibara K, Saito N, Sato T, Suzuki A, Hasegawa Y, Friedman JM et al. CBS9106 is a novel reversible oral CRM1 inhibitor with CRM1 degrading activity. Blood 2011; 118: 3922-3931.
20. Etchin J, Sun Q, Kentsis A, Farmer A, Zhang ZC, Sanda T et al. Anti-leukemic activity of nuclear export inhibitors that spare normal hematopoietic cells. Leukemia 2012; 27: 66-74.
21. Lapalombella R, Sun Q, Williams K, Tangeman L, Jha S, Zhong Y et al. Selective inhibitors of nuclear export show that CRM1/XPO1 is a target in chronic lymphocytic leukemia. Blood 2012; 120: 4621-4634.
22. Ranganathan P, Yu X, Na C, Santhanam R, Shacham S, Kauffman M et al. Preclinical activity of a novel CRM1 inhibitor in acute myeloid leukemia. Blood 2012; 120: 1765-1773.
23. Tai YT, Chang BY, Kong SY, Fulciniti M, Yang G, Calle Y et al. Bruton tyrosine kinase inhibition is a novel therapeutic strategy targeting tumor in the bone marrow microenvironment in multiple myeloma. Blood 2012; 120: 1877-1887.
24. Tai YT, Fulciniti M, Hideshima T, Song W, Leiba M, Li XF et al. Targeting MEK induces myeloma-cell cytotoxicity and inhibits osteoclastogenesis. Blood 2007; 110: 1656-1663. (Pubitemid 47443984)
25. Tai YT, Dillon M, Song W, Leiba M, Li XF, Burger P et al. Anti-CS1 humanized monoclonal antibody HuLuc63 inhibits myeloma cell adhesion and induces antibody-dependent cellular cytotoxicity in the bone marrow milieu. Blood 2008; 112: 1329-1337.
26. Zhan F, Barlogie B, Arzoumanian V, Huang Y, Williams DR, Hollmig K et al. Gene-expression signature of benign monoclonal gammopathy evident in multiple myeloma is linked to good prognosis. Blood 2007; 109: 1692-1700. (Pubitemid 46239604)
27. Zhan F, Huang Y, Colla S, Stewart JP, Hanamura I, Gupta S et al. The molecular classification of multiple myeloma. Blood 2006; 108: 2020-2028. (Pubitemid 44395016)
28. Shaughnessy Jr JD, Zhan F, Burington BE, Huang Y, Colla S, Hanamura I et al. A validated gene expression model of high-risk multiple myeloma is defined by deregulated expression of genes mapping to chromosome 1. Blood 2007; 109: 2276-2284. (Pubitemid 46425864)
29. Gutierrez NC, Ocio EM, de Las Rivas J, Maiso P, Delgado M, Ferminan E et al. Gene expression profiling of B lymphocytes and plasma cells from Waldenstrom's macroglobulinemia: comparison with expression patterns of the same cell counterparts from chronic lymphocytic leukemia, multiple myeloma and normal individuals. Leukemia 2007; 21: 541-549.
30. Mattioli M, Agnelli L, Fabris S, Baldini L, Morabito F, Bicciato S et al. Gene expression profiling of plasma cell dyscrasias reveals molecular patterns associated with distinct IGH translocations in multiple myeloma. Oncogene 2005; 24: 2461-2473. (Pubitemid 40593037)
31. Mulligan G, Mitsiades C, Bryant B, Zhan F, Chng WJ, Roels S et al. Gene expression profiling and correlation with outcome in clinical trials of the proteasome inhibitor bortezomib. Blood 2007; 109: 3177-3188. (Pubitemid 46572502)
32. Quinn J, Glassford J, Percy L, Munson P, Marafioti T, Rodriguez-Justo M et al. APRIL promotes cell-cycle progression in primary multiple myeloma cells: influence of D-type cyclin group and translocation status. Blood 2011; 117: 890-901.
33. Tai YT, Li XF, Breitkreutz I, Song W, Neri P, Catley L et al. Role of B-cell-activating factor in adhesion and growth of human multiple myeloma cells in the bone marrow microenvironment. Cancer Res 2006; 66: 6675-6682. (Pubitemid 44085624)
34. Moreaux J, Legouffe E, Jourdan E, Quittet P, Reme T, Lugagne C et al. BAFF and APRIL protect myeloma cells from apoptosis induced by interleukin 6 deprivation and dexamethasone. Blood 2004; 103: 3148-3157. (Pubitemid 38451693)
35. McMillin DW, Delmore J, Weisberg E, Negri JM, Geer DC, Klippel S et al. Tumor cellspecific bioluminescence platform to identify stroma-induced changes to anticancer drug activity. Nat Med 2010; 16: 483-489.
36. Takayanagi H, Kim S, Koga T, Nishina H, Isshiki M, Yoshida H et al. Induction and activation of the transcription factor NFATc1 (NFAT2) integrate RANKL signaling in terminal differentiation of osteoclasts. Dev Cell 2002; 3: 889-901. (Pubitemid 35460788)
37. Yagi M, Miyamoto T, Sawatani Y, Iwamoto K, Hosogane N, Fujita N et al. DC-STAMP is essential for cell-cell fusion in osteoclasts and foreign body giant cells. J Exp Med 2005; 202: 345-351. (Pubitemid 41126951)
38. Kukita T, Wada N, Kukita A, Kakimoto T, Sandra F, Toh K et al. RANKL-induced DC-STAMP is essential for osteoclastogenesis. J Exp Med 2004; 200: 941-946. (Pubitemid 39362930)
39. Tiedemann RE, Zhu YX, Schmidt J, Shi CX, Sereduk C, Yin H et al. Identification of molecular vulnerabilities in human multiple myeloma cells by RNA interference lethality screening of the druggable genome. Cancer Res 2012; 72: 757-768.
40. Jeffers JR, Parganas E, Lee Y, Yang C, Wang J, Brennan J et al. Puma is an essential mediator of p53-dependent and-independent apoptotic pathways. Cancer Cell 2003; 4: 321-328. (Pubitemid 37329796)
41. You H, Pellegrini M, Tsuchihara K, Yamamoto K, Hacker G, Erlacher M et al. FOXO3a-dependent regulation of Puma in response to cytokine/growth factor withdrawal. J Exp Med 2006; 203: 1657-1663. (Pubitemid 44036270)
42. Grinberg AV, Hu CD, Kerppola TK. Visualization of Myc/Max/Mad family dimers and the competition for dimerization in living cells. Mol Cell Biol 2004; 24: 4294-4308. (Pubitemid 41071000)
43. Golomb L, Bublik DR, Wilder S, Nevo R, Kiss V, Grabusic K et al. Importin 7 and exportin 1 link c-Myc and p53 to regulation of ribosomal biogenesis. Mol Cell 2012; 45: 222-232.
44. van der Watt PJ, Leaner VD. The nuclear exporter, Crm1, is regulated by NFY and Sp1 in cancer cells and repressed by p53 in response to DNA damage. Biochim Biophys Acta 2011; 1809: 316-326.
45. Hideshima T, Mitsiades C, Tonon G, Richardson PG, Anderson KC. Understanding multiple myeloma pathogenesis in the bone marrow to identify new therapeutic targets. Nat Rev Cancer 2007; 7: 585-598. (Pubitemid 47106630)
46. Mutka SC, Yang WQ, Dong SD, Ward SL, Craig DA, Timmermans PB et al. Identification of nuclear export inhibitors with potent anticancer activity in vivo. Cancer Res 2009; 69: 510-517.